The NYECC Results Page: Introducing the Latest Eye Cancer Directory

In our previous blog, we unveiled Dr. Finger’s Results page, the first public database of its kind to report a doctor’s treatment outcomes. With the power of the world-wide-web at our fingertips, it is now easier than ever to browse for healthcare options. Search engines, with the simple press of a button, are able to provide patients with a virtually infinite list of specialists available to them locally, regionally, even internationally.

So, shouldn’t it be just as easy to know how successful these specialists are? How can patients choose the best doctor without knowing their past performance? These questions motivated the creation of Dr. Finger’s Results page, a launch that was met with glowing approval from across both patient and scientific communities. And now, this page is more comprehensive than ever!

Understanding the Report

Choroidal melanoma, iris-ciliary body melanoma, and squamous conjunctival malignancy are three of the most common conditions treated at The New York Eye Cancer Center. Once treated for these select diseases (whether through plaque radiation, chemotherapy, cryotherapy, and so on), patients are routinely seen at NYECC in follow-up visits, where they are monitored for any changes in tumor activity and quality of life.

Starting from December 1, 2017, each NYECC patient seen in these follow-up visits is anonymously entered in our Result’s page database — information that becomes immediately accessible on our website. These results are updated weekly, and with Dr. Finger’s practice spanning over 30 years, the database will continue to grow moving forward.

For each disease, we report on:

– Patients Entered: The number of patients included in these results, which grows with every week once patients are seen by Dr. Finger in follow-up.
– Visual Acuity: The average and median (most common) visual acuity, or eye chart test score, after finishing treatment.
 Local Tumor Destruction: The percentage of patients whose tumors are successfully eliminated through treatment.
– Initial Eye Removal: The percentage of patients who have undergone enucleation (eye removal) surgery prior to being treated by Dr. Finger at NYECC.
– Metastases: The percentage of patients whose tumors have spread to other organs after treatment.
– Average Follow Up: Number of years after treatment before additional treatments are required.

The data, located on our Results page and observable through an interactive table, reports on patients treated only by Dr. Finger. Patient data is strictly confidential, HIPPA-compliant and, once again, anonymous.

What’s New

Our Results page has a new look! Rather than having to observe all reports at once, we have implemented a ‘choose your results’ feature. This cancer directory allows you to choose which of these three diseases you would like to observe. Choroidal Melanoma, Iris Ciliary Body Melanoma, Squamous Conjunctival Malignancy — each of these reports now has its own page and table. These pages will be a source of information specialized to each disease; the result is a streamlined, organized process for eye cancer patients across the world. Here is a shortcut to the directory you can find on our page:


Choose your cancer below to view results:

 

Choroidal Melanoma »

 

Iris Ciliary Body Melanoma »

 

Squamous Conjunctival Malignancy »

 


The launch of our results page is the first step, and we encourage other centers to join us in this effort. The Eye Cancer Foundation will offer assistance to any center or solo practitioner in setting up a page akin to the new NYECC Results page.

Let’s hold ourselves accountable to our outcomes and empower patients to make their life-changing choice of eye cancer specialist based on visible results.


Patient Stories

"Very well treated by Dr. Finger. He explained everything I needed to know about my issue with detail and attention, putting me at ease and giving me confidence to handle this problem for the rest of my life.”
N.N.

Read More

REQUEST AN APPOINTMENT

  • This field is for validation purposes and should be left unchanged.

CONNECT AND SHARE